Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease.
D'Alessandro A, Le K, Lundt M, Li Q, Dunkelberger EB, Cellmer T, Worth AJ, Patil S, Huston C, Grier A, Dzieciatkowska M, Stephenson D, Eaton WA, Thein SL. D'Alessandro A, et al. Among authors: dunkelberger eb. Haematologica. 2024 Aug 1;109(8):2639-2652. doi: 10.3324/haematol.2023.284831. Haematologica. 2024. PMID: 38450513 Free PMC article. Clinical Trial.
Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.
Metaferia B, Cellmer T, Dunkelberger EB, Li Q, Henry ER, Hofrichter J, Staton D, Hsieh MM, Conrey AK, Tisdale JF, Chatterjee AK, Thein SL, Eaton WA. Metaferia B, et al. Among authors: dunkelberger eb. Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2210779119. doi: 10.1073/pnas.2210779119. Epub 2022 Sep 26. Proc Natl Acad Sci U S A. 2022. PMID: 36161945 Free PMC article.
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Xu JZ, Conrey A, Frey I, Gwaabe E, Menapace LA, Tumburu L, Lundt M, Lequang T, Li Q, Glass K, Dunkelberger EB, Iyer V, Mangus H, Kung C, Dang L, Kosinski PA, Hawkins P, Jeffries N, Eaton WA, Lay Thein S. Xu JZ, et al. Among authors: dunkelberger eb. Blood. 2022 Nov 10;140(19):2053-2062. doi: 10.1182/blood.2022015403. Blood. 2022. PMID: 35576529 Free PMC article. Clinical Trial.
Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA. Henry ER, et al. Among authors: dunkelberger eb. Blood. 2021 Sep 30;138(13):1172-1181. doi: 10.1182/blood.2021012070. Blood. 2021. PMID: 34197597 Free PMC article.
Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease.
Henry ER, Cellmer T, Dunkelberger EB, Metaferia B, Hofrichter J, Li Q, Ostrowski D, Ghirlando R, Louis JM, Moutereau S, Galactéros F, Thein SL, Bartolucci P, Eaton WA. Henry ER, et al. Among authors: dunkelberger eb. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15018-15027. doi: 10.1073/pnas.1922004117. Epub 2020 Jun 11. Proc Natl Acad Sci U S A. 2020. PMID: 32527859 Free PMC article.
Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease.
Li Q, Henry ER, Hofrichter J, Smith JF, Cellmer T, Dunkelberger EB, Metaferia BB, Jones-Straehle S, Boutom S, Christoph GW, Wakefield TH, Link ME, Staton D, Vass ER, Miller JL, Hsieh MM, Tisdale JF, Eaton WA. Li Q, et al. Among authors: dunkelberger eb. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E689-E696. doi: 10.1073/pnas.1619054114. Epub 2017 Jan 17. Proc Natl Acad Sci U S A. 2017. PMID: 28096387 Free PMC article.
13 results